FibroBiologics reported net income of -$4.12M for the quarter ended Jun 2026. This income statement covers 15 quarters of results from Dec 2022 through Jun 2026, standardized by Business Quant from the company’s SEC filings.
| Income Statement | Dec2022 | Mar2023 | Jun2023 | Sep2023 | Dec2023 | Mar2024 | Jun2024 | Sep2024 | Dec2024 | Mar2025 | Jun2025 | Sep2025 | Dec2025 | Mar2026 | Jun2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Shares Outstanding (Entity)Shares Outstanding (Entity.) | 1.85M | 1.85M | 1.85M | 1.85M | 1.63M | 1.64M | 1.76M | 1.73M | 1.89M | 1.91M | 2.09M | 2.57M | 3.33M | 3.77M | 6.66M |
| Operating items | |||||||||||||||
| Research & DevelopmentR&D | 0.48M | 0.55M | 0.57M | 0.77M | 0.96M | 0.97M | 1.21M | 1.36M | 1.78M | 2.04M | 2.79M | 0.80M | 2.95M | 1.66M | |
| Selling, General & AdministrativeSG&A | 1.79M | 1.55M | 1.48M | 1.71M | 2.49M | 2.25M | 2.14M | 2.36M | 2.75M | 2.45M | 2.25M | 1.79M | 2.12M | 2.38M | |
| Operating ExpensesOpex | 2.27M | 2.09M | 2.05M | 2.48M | 3.45M | 3.22M | 3.35M | 3.71M | 4.53M | 4.49M | 5.04M | 2.59M | 5.07M | 4.03M | |
| Operating IncomeOp. Inc | -2.27M | -2.09M | -2.05M | -2.48M | -3.45M | -3.22M | -3.35M | -3.71M | -4.53M | -4.49M | -5.04M | -2.59M | -5.07M | -4.03M | |
| EBIT | -2.27M | -2.09M | -2.05M | -2.48M | -3.45M | -3.22M | -3.35M | -3.71M | -4.53M | -4.49M | -5.04M | -2.59M | -5.07M | -4.03M | |
| Non-operating items | |||||||||||||||
| Non Operating Interest Expenses | 0.14M | 0.01M | 0.00M | 0.00M | 0.01M | 0.01M | 0.01M | 0.20M | 0.00M | 0.01M | |||||
| Interest & Investment IncomeInt & Inv Inc | 0.04M | 0.07M | 0.08M | 0.06M | 0.10M | 0.05M | 0.07M | 0.03M | 0.02M | 0.01M | |||||
| Other Non Operating IncomeOther Non Op Inc. | -0.06M | -0.14M | 0.03M | 0.85M | 0.23M | -0.45M | -0.62M | -0.85M | -0.81M | -0.00M | -0.09M | ||||
| Non Operating IncomeNon Op. Inc. | -0.01M | -0.14M | -0.20M | 2.85M | 0.61M | -0.43M | -0.17M | -0.74M | -0.65M | 0.07M | -0.08M | ||||
| Net income details | |||||||||||||||
| EBT | -2.40M | -2.10M | -2.05M | -2.48M | -3.42M | -3.16M | -3.28M | -3.65M | -4.43M | -4.44M | -4.96M | -2.77M | -5.05M | -4.03M | |
| Profit After TaxPAT | -2.42M | -2.16M | -2.19M | -9.72M | -8.46M | 0.90M | -0.50M | -3.10M | -4.97M | -4.66M | -5.78M | -3.24M | -5.00M | -4.12M | |
| Income from Continuing OperationsIncome (Continuing) | -2.40M | -2.10M | -2.05M | -2.48M | -3.42M | -3.16M | -3.28M | -3.65M | -4.43M | -4.44M | -4.96M | -2.77M | -5.05M | -4.03M | |
| Consolidated Net IncomeConsol Net Inc. | -2.40M | -2.10M | -2.05M | -2.48M | -3.42M | -3.16M | -3.28M | -3.65M | -4.43M | -4.44M | -4.96M | -2.77M | -5.05M | -4.03M | |
| Income towards Parent CompanyParent Net Inc | -2.40M | -2.10M | -2.05M | -2.48M | -3.42M | -3.16M | -3.28M | -3.65M | -4.43M | -4.44M | -4.96M | -2.77M | -5.05M | -4.03M | |
| Preferred Dividend PaymentsPref Dividends | -2.57M | ||||||||||||||
| Net Income towards Common StockholdersNet Income | -4.99M | -2.16M | -2.19M | -9.72M | -8.46M | 0.90M | -0.50M | -3.10M | -4.97M | -4.66M | -4.96M | -2.77M | -5.05M | -4.03M | |
| Additional items | |||||||||||||||
| EPS (Basic) | -3.53 | -1.53 | -1.55 | -6.88 | -5.43 | 0.55 | -0.30 | -1.89 | -2.71 | -2.41 | -2.31 | -1.24 | -1.34 | -0.64 | |
| EPS (Diluted) | -3.53 | -1.53 | -1.55 | -6.88 | -5.43 | 0.55 | -0.30 | -1.89 | -2.71 | -2.41 | -2.31 | -1.24 | -1.34 | -0.64 | |
| Shares Outstanding | 1.41M | 1.41M | 1.41M | 1.41M | 1.41M | 1.56M | 1.64M | 1.68M | 1.64M | 1.83M | 1.93M | 2.15M | 2.23M | 3.77M | 6.27M |
| Shares Outstanding (Diluted)Shares Outstanding (Dil.) | 1.41M | 1.41M | 1.41M | 1.41M | 1.41M | 1.56M | 1.64M | 1.68M | 1.64M | 1.83M | 1.93M | 2.15M | 2.23M | 3.77M | 6.27M |
| EBITDA | -2.27M | -2.09M | -2.05M | -2.48M | -3.45M | -3.22M | -3.35M | -3.71M | -4.53M | -4.49M | -5.04M | -2.59M | -5.07M | -4.03M | |
| Interest ExpensesInt Expense | 0.14M | 0.01M | 0.00M | 0.00M | 0.01M | 0.01M | 0.01M | 0.20M | 0.00M | 0.01M |